Svena Verma

Svena Verma

Auto-generated profile, based on publicly available information

Svena Verma

Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. 1

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Multisensory Research
Verified
Journal Article
Open access
PDF file
AKAmy Kalia
Amy Kalia
RHRose Hopkins
Rose Hopkins
DJDavid Jin
David Jin
LYLindsay Yazzolino
Lindsay Yazzolino
SVSvena Verma
Svena Verma
PSPawan Sinha
Pawan Sinha
Graphical information, such as illustrations, graphs, and diagrams, are an essential complement to text for conveying knowledge about the world. Although graphics can be communicated well via the visual modality, conveying this information via touch has proven to be challenging. The lack of easily comprehensible tactile graphics poses a problem for the blind. In this paper, we advance a hypothesis for the limited effectiveness of tactile graphics. The hypothesis contends that conventional graphics that rely upon embossings on two-dimensional surfaces do not allow the deployment of tactile exploratory procedures that are crucial for assessing global shape. Besides potentially accounting for some of the shortcomings of current approaches, this hypothesis also serves a prescriptive purpose by suggesting a different strategy for conveying graphical information via touch, one based on cutouts. We describe experiments demonstrating the greater effectiveness of this approach for conveying shape and identity information. These results hold the potential for creating more comprehensible tactile drawings for the visually impaired while also providing insights into shape estimation processes in the tactile modality.

17 June 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
MEK inhibitors (MEKi) have shown limited success as a treatment for MAPK/ERK pathway–dependent cancers due to various resistance mechanisms tumor cells can employ. CH5126766 (CKI27) is an inhibitor that binds to MEK and prevents release of RAF, reducing the relief of negative feedback commonly observed with other MEKis. We observed that CKI27 increased MHC expression in tumor cells and improved T cell–mediated killing. Yet, CKI27 also decreased T-cell proliferation, activation, and cytolytic activity by inhibiting the MAPK/ERK pathway that is activated downstream of T-cell receptor signaling. Therefore, we aimed to balance the positive and negative immunomodulatory effects of MEKis for optimal combination with immunotherapy. Intermittent administration of CKI27 allowed T cells to partially recover and costimulation via GITR and OX-40 agonist antibodies completely alleviated inhibition of function. In Kras mutant lung and colon tumor mouse models, intermittent CKI27 and anti-GITR significantly decreased tumor growth and prolonged survival when further combined with CTLA-4 immune checkpoint blockade. Moreover, this triple combination increased CD8+ and CD4+ T-cell proliferation, activation, and effector/memory subsets in the tumor-draining lymph nodes and tumors and led to intratumoral regulatory T-cell destabilization. These data, collectively, will allow for more informed decisions when optimizing combination regimens by overcoming resistance, reducing toxicity, and generating long-term immune responses.

17 June 2026
Verified
Other
Open access
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 6. Intermittent CKI27 treatment and GITR co-stimulation relieves expression of co-inhibitory markers. (A) Gating strategy for all T cell activation assays. (B) Representative dot plot data for FACS analysis of co-inhibitory markers expressed by CD8+ T cells.

17 June 2026
Verified
Other
Open access
PDF file
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 3. MEK inhibition with CKI27 increases HLA and checkpoint ligand expression. (A-B) Human tumor cell lines were treated with DMSO or CKI27 for 72hr and either with or without IFNγ (10ng/mL) for the last 24hr; n=3. FACS analysis of (A) HLA-ABC and HLA-DR and (B) PD-L1, CD80 and CD86 surface expression. MFI values are shown as mean±SEM.

17 June 2026
Verified
Other
Open access
PDF file
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 8. Intermittent CKI27 treatment and GITR co-stimulation relieves expression of activation markers. Representative dot plot data for FACS analysis of activation markers expressed by CD8+ T cells.

17 June 2026
Verified
Other
Open access
PDF file
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 1. MEK inhibition with CKI27 increases MHC and checkpoint ligand expression. (A-B) Murine tumor cell lines were treated with DMSO or CKI27 for 72 hr and either with or without IFNγ (5ng/mL) for the last 24hr; n=3. FACS analysis of (A) MHC-I (H2Kb/Kd and H2Db/Dd) and MHC-II and (B) PD-L1, CD80 and CD86 surface expression. Median fluorescence intensity (MFI) values were normalized to DMSO and log transformed. Data are shown as mean±SEM.